NCT02711553 2025-08-03A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerEli Lilly and CompanyPhase 2 Active not recruiting309 enrolled 22 charts